Clinical Trials Browser

Phase 1/2 × INDUSTRY × tagraxofusp × Clear all

NCT02268253 2025-01-06

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Phase 1/2 Completed

82 enrolled 15 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02270463 2024-10-17

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Phase 1/2 Terminated

16 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

138 enrolled 23 charts 2 FDA

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT02661022 2024-04-17

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 1/2 Terminated

9 enrolled 13 charts

Multiple Myeloma, Recurrence